EC1
stringlengths 22
351
| CT_title
stringlengths 38
384
|
|---|---|
[inclusion] the following laboratory results must be present: Serum amylase and lipase ≤ 1.5 x ULN | A Phase III Multi-center, Open-label, Randomized Study of the Efficacy of Nilotinib Versus Imatinib in Adult Patients With Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib |
[exclusion] subjects with epilepsy with or without cognitive complaints will be excluded from participation for: Status epilepticus in the past year | Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits: a Randomized, Double-blind, Placebo-controlled Trial |
[exclusion] prior treatment with avelumab, a PARP inhibitor or MEK inhibitor | A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF COMBINATIONS OF AVELUMAB, BINIMETINIB AND TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RAS-MUTANT SOLID TUMORS |
[inclusion] KPS equal to or greater than 70 | Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen |
[inclusion] the patient must have been diagnosed with clinically definite MS, at the time of informed consent | Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study |
[exclusion] confirmed dysphagia that would preclude self-administration of ambroxol up to 6 tablets daily for the duration of day 1 to day 550/Month 18 | A Clinical Trial to Demonstrate Clinical Efficacy on Cognitive, Neuropsychiatric and Functional Outcomes of Ambroxol in New and Early Patients With Prodromal and Mild Dementia With Lewybodies |
[exclusion] hyperkalemia or hyperuricemia | A 24-week, Double-blind, Randomized, Placebo-controlled, Multicenter Study, to Evaluate the Effectiveness of Cyclosporine 2,5 mg/kg/Day Bid Twice a Week on Reducing Relapse Rate, in Maintenance Patients With Chronic Plaque Psoriasis |
[inclusion] participant has an index VOC. The index VOC is any VOC that required admission to a healthcare facility and treatment with parenteral pain medication. An admission for the index VOC includes: for an acute episode of pain with no other cause other than a vaso- occlusive event that includes the following: Uncomplicated VOC, | A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises |
[exclusion] current use of clonidine or solifenacin. (If patients have been off of these for one month, then they are eligible) | A Phase II Randomized Study of Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients Receiving Adjuvant Hormonal Therapy |
[exclusion] presence of pruritus less than three months | Assessment of Montelukast Efficacy in the Treatment of Refractive Uremic Pruritus |
[inclusion] polymerase chain reaction-amplifiable clonal CDRIII rearrangement of the IgV_H | Pivotal Study for High Dose Therapy and Autologous Stem Cell Transplantation in Early Stages of CLL |
[inclusion] patients with an autoimmune disorder of the central or peripheral nervous system will be eligible; this will include: Rasmussen's encephalitis | High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases |
[inclusion] no prior endocrine therapy for breast cancer | Surgical Therapy With or Without Axillary Node Clearance for Breast Cancer in the Elderly Who Receive Adjuvant Therapy With Tamoxifen. |
[inclusion] R/R T-NHL with measurable (≧1.5cm) lesions confirmed by pathological immunohistochemistry or flow cytometry | Humanized CD7 CAR T-cell Therapy for R/R CD7+ T Cell Lymphoma |
[exclusion] women treated with oral bisphosphonates or calcitonin for 3 months within the last year (3 month washout period) | The Effect of Bisphosphonate on Bone Mass and Bone Turnover in Elderly, Postmenopausal Women With Breast Cancer Following Initiation of Aromatase Inhibitor Therapy |
[exclusion] significant weight loss within the past 6 months or since the liver biopsy | Insulin Resistance in Non-alcoholic Fatty Liver Disease (Protocol Drug Change From Project Career Development Award (CDA)-2-044-08S) |
[inclusion] paO2/FiO2<300 on PEEP≥5 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Preliminary Efficacy Study of IC14 in Acute Respiratory Distress Syndrome |
[exclusion] patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrollment | An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer |
[exclusion] have previously received intestinal stent implantation and the intestinal stent has not been explanted until screening | A Randomized, Double-blind, Multicenter, PhaseⅡ/Ⅲ Clinical Study of Serplulimab (HLX10) in Combination With Bevacizumab (HLX04) and Chemotherapy (XELOX) Versus Placebo in Combination With Bevacizumab (HLX04) and Chemotherapy (XELOX) in First-line Treatment of Patients With Metastatic Colorectal Cancer (mCRC) |
[exclusion] has any of the following drug therapy: Received nucleoside or nucleotide therapy whether approved or investigational | A Randomized, Open-label, Controlled, Multi-center Two-year Study Comparing Efficacy and Safety of Telbivudine, 600 mg PO in Combination With Peginterferon Alpha-2a sq 180 µg With Peginterferon Alpha-2a Monotherapy, and With Telbivudine Monotherapy in Treatment naïve Patients With HBeAg-positive CHB. |
[exclusion] history of immunization within 4 weeks of study participation or plan to receive non- IIV vaccination within 4 weeks of receiving IIV | B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults |
[exclusion] autologous HSCT within 3 months of the first dose of GEN3014 | An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies |
[exclusion] CHF: NYHA > II | Effect of Sildenafil on Endothelial Function |
[inclusion] HIV-1 infected partner of an HIV-uninfected volunteer who meets study eligibility | A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa |
[exclusion] patients who develop conditions in which the administration is not possible rinses | Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7% to Reduce the Rate Oral Colonization by Gram-negative Bacteria in Patients With Chemotherapy |
[exclusion] cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair) | Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Oral Doses of BI 1569912 in Healthy Male Japanese Subjects (Single-blind, Partially Randomized Within Dose Groups, Placebo-controlled, Parallel-group Design) |
[exclusion] patients expected to require rescue on Day 1 of the study | A Multicenter, Randomized, Double-Blind and Open-label Phase III Study To Compare The Efficacy And Safety Of Eltrombopag With Placebo In Chinese Chronic ITP Patients |
[exclusion] metabolic disease or uncontrolled systemic disease | Randomized Phase II Clinical Study of Radiation Therapy, Hormone Therapy and Chemotherapy With Docetaxel Versus Radiation Therapy and Hormone Therapy in Patients With High-Risk Localized Prostate Cancer (Stage III and IV)" |
[exclusion] cancer other than mesothelioma within 5 years prior to start of study treatment EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumours [Ta (noninvasive tumour), Tis (carcinoma in situ) & T1 (tumour invading lamina propria)] | Trial of Sorafenib in Malignant Mesothelioma Previously Treated With Platinum-based Chemotherapy |
[exclusion] arthritic changes (Kellgren Lawrence scale >2) or axial leg deformity (valgus > 6 deg) | Prospective, Randomised, Double Blinded Trial Comparing Effectiveness of Platelet Rich Plasma or Placebo in a Primary Meniscal Tear Treatment |
[inclusion] acute lymphocytic or myeloid leukemia (ALL or AML) in 1 of the following categories: Failed to achieve a complete response (CR) with initial induction regimen | PHASE I STUDY OF CONTINUOUS INFUSION CARBOPLATIN AND TOPOTECAN IN THE TREATMENT OF RELAPSED ACUTE LEUKEMIA AND BLAST CRISIS CHRONIC MYELOGENOUS LEUKEMIA |
[exclusion] history of gynecological procedures (including genital piercing) on the external genitalia, vagina or cervix within the last 14 days; and | Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel Using the Bat 24 Regimen Versus Daily and Pericoital Dosing |
[exclusion] receipt of immunosuppressive medications included the inhaled or local immunosuppressant drugs within 45 days prior to Study | A Phase 1 Single Center, Parallel, Open Label Bridging Study to Evaluate on the Safety, Pharmacokinetic, Pharmacodynamics and Anti-drug Antibodies (ADA) of a Single Intramuscular Doses of SYN023 in Healthy Adult Subjects |
[inclusion] T3, N0 OR T1-3, N+ OR T4, Nx | A Phase II Trial of Neoadjuvant Chemotherapy With Nimotuzumab Plus Nanoparticle Albumin-bound Paclitaxel and Cisplatin Followed by Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of Esophagus |
[inclusion] participants should be taking 1 of the following permissible highly active antiretroviral therapy (HAART) regimens for HIV continuously for 12 weeks prior to screening: Boosted atazanavir (atazanavir with ritonavir) plus Truvada® (tenofovir, emtricitabine) or equivalent components | An Open Label,Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1) |
[inclusion] diabetic subjects must have been receiving as their only current anti-diabetic therapy stable doses of sulfonylureas for the last 2 months | Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes |
[inclusion] previously treated patients must be neurologically stable for 4 weeks after completion of appropriate therapy | Evaluation Of Celecoxib In Combination With Docetaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer Patients Previously Treated With Platinum Based Chemotherapy |
[exclusion] any other malignancies within the past 5 years except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri | Phase II Trial of Rituximab (R) Augmentation Following R-CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma (DLBCL) |
[inclusion] no other malignancy within the past 2 years except surgically cured carcinoma in situ of the cervix or basal cell or squamous cell skin cancer | Dose Escalation of Temozolomide in Combination With Thiotepa and Carboplatin With Autologous Stem Cell Rescue in Patients With Malignant Brain Tumors With Minimal Residual Disease |
[exclusion] uncontrolled intercurrent illness including, but not limited to the following that may limit interpretation of results or that could increase risk to the patient at the discretion of the investigator: Uncontrolled Type I or II diabetes despite optimal medical management | A Phase 2 Study of Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma |
[exclusion] patients with a history of seizure disorder other than Infantile Febrile Seizures | A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up |
[inclusion] able to undergo radiotherapy NOTE: *Abnormal blood counts allowed if there is bone marrow biopsy or aspirate proven bone marrow involvement by rhabdomyosarcoma | Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma |
[exclusion] DONOR: Significant medical conditions (e.g. immunosuppressive therapy) that would make the donor an unsuitable T cell donor | Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Patients With Relapsed AML |
[inclusion] note: There is no HIV-1 RNA level eligibility criterion | A Randomized, Placebo-Controlled Trial of Pentoxifylline to Improve Endothelial Function in HIV-Infected Patients Not Requiring Antiretroviral Therapy |
[inclusion] hIV-negative as determined by the HIV algorithm applied at Screening/Pre- Enrolment | A Follow-On, Open-Label Trial To Assess Continued Safety Of And Adherence To The Dapivirine (25 Mg) Vaginal Ring-004 In Healthy, HIV-Negative Women |
[inclusion] have a positive history of ocular allergies and a positive skin test reaction to ragweed pollen as confirmed by the allergic skin test given to the subject within 24 months of the subject's Visit 1 | A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Methodology Development Environmental Clinical Trial With Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects With Seasonal Allergic Conjunctivitis |
[exclusion] concomitant use of 5 phosphodiesterase inhibitors | The Treatment of Hypertension Associated With Severe Preeclampsia. A Randomize Controlled Trial of Urapidil Versus Nicardipine. The Uranic Trial |
[exclusion] receiving any active anti-cancer therapy while on study treatment | Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors |
[exclusion] patient with prior ocular surgeries within previous 6 months | The Efficacy and Safety of Topical Vitamin D Drop on Meibomian Gland Function in Patients With Meibomian Gland Dysfunction |
[inclusion] baseline methacholine (PC20) ≤ 16 mg/mL | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Three-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of ASM-024 Administered by Inhalation Once Daily to Subjects With Mild Allergic Asthma |
[exclusion] positive sputum, epiglottic, or bronchoalveolar lavage culture for Mycobacterium abscessus during the 2 years prior to enrollment | Randomized Controlled Study of Sildenafil in Children and Young Adults With Mild to Moderate Cystic Fibrosis Lung Disease |
[inclusion] complete remission before hematopoietic stem cell transplantation (HSCT) | Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia |
[inclusion] no significant cardiovascular disease, defined as any of the following, within the past 6 months: Myocardial infarction | Dynamic Contrast Enhanced MRI (DCE-MRI) Assessment of the Vascular Changes Induced With Bevacizumab Alone and in Combination With Interferon-α in Patients With Advanced Renal Cell Carcinoma |
[exclusion] grade 2 or greater diarrhea of any cause at time of study entry | Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROG |
[exclusion] plasma cell leukemia, Smouldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome, Primary refractory MM | A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA |
[inclusion] disease duration ≤3 years | Efficacy, Safety and Tolerability of Growth Hormone in Patients With Amyotrophic Lateral Sclerosis as add-on Therapy to Riluzole |
[inclusion] patient must be between the ages of 18 and 65 years and meet the institution's criteria for renal transplantation for end-organ failure | Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion |
[inclusion] relapsed or refractory NKG2D ligand positive AML (meeting one of the following conditions): Ineffectively after first or multiple remedial treatments | Clinical Trial for the Safety and Efficacy of NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia |
[exclusion] has a history of neuroleptic malignant syndrome | A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 Using Risperidone as an Active Control in Subjects Experiencing an Acute Episode of Schizophrenia |
[inclusion] no active inflammatory bowel disease | Gemcitabine Plus Irinotecan in Patients With Esophageal Cancer, Phase II |
[inclusion] diagnosed with atopic dermatitis by a CHW pediatric dermatologist | Treatment Of Vitamin D Deficiency And Effect On Atopic Dermatitis Severity |
[exclusion] use of prescription medications | The Impact of Free Fatty Acid Reduction on Vascular Function and Skeletal Muscle Glucose Utilization in Type 2 Diabetes Mellitus |
[exclusion] peripheral sensitive neuropathy with functional impairment (> grade 1 acc. to CTCAE version 5.0 (see appendix)) | Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Cancer |
[exclusion] systolic BP >140 mmHg or <90 mmHg or diastolic BP >90 mmHg or <60 mmHg at Screening with 1 repeat allowed per Investigator discretion at Screening and Day -1 (and Day 14 for subjects in the crossover treatment group period 2) | An Open-Label, Partial Crossover, Single-Dose Study to Evaluate the Pharmacokinetics, Dose-Proportionality, and Safety/Tolerability of Tablet Versus Capsule Formulations of KBP 5074 in Healthy Subjects |
[exclusion] previous ocular surgery | PRevention of Macular EDema After Cataract Surgery |
[exclusion] previous treatment with biologic therapies other than anti-TNF for RA | A Phase 2 Exploratory Study of Mavrilimumab Versus Anti-tumor Necrosis Factor in Subjects With Rheumatoid Arthritis |
[inclusion] gastric cancer (including gastric and EGJ cancers): at least 2 prior systemic regimens in adjuvant, advanced, or metastatic setting and, as appropriate, a human epidermal growth factor receptor 2 (HER2) targeted agent | An Open Label Study of SC-007 in Subjects With Advanced Cancer |
[exclusion] the eye with the worse visual acuity will be selected as the study eye | A Phase I/IIa Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis |
[inclusion] completed cancer staging with CT-abdomen and CT-thorax/X-thorax according to hospital's standard of care | Targeted Therapy With Imatinib for Treatment of Poor Prognosis Mesenchymal-type Resectable Colon Cancer: a Proof-of-concept Study in the Preoperative Window Period. |
[exclusion] unstable or deteriorating cardiac disease within the preceding 6 months including but not limited to unstable angina pectoris, myocardial infarction (heart attack), heart failure requiring hospitalization, poorly controlled heart arrhythmia, or significant pericardial effusion/fluid collection around the heart | A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung Disease |
[exclusion] have, in the opinion of investigator, uncontrolled co-morbid conditions, such as diabetes mellitus, hypertension and heart failure [e.g. New York Heart Association (NYHA) class III (e.g. less than ordinary activity causes fatigue, palpitation, or dyspnoea), and class IV (e.g. Symptoms of heart failure at rest)] that will affect the study | A Randomised Placebo-controlled Trial of Anti-ST2 in COPD (COPD-ST2OP) |
[exclusion] patients receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) other than ibrutinib or acalabrutinib within 2 weeks of Cycle 1/Day 1 with the following exceptions: Limited palliative radiation is allowed if completed > 1 weeks of C1D1 | A Phase II Study of Copanlisib to Deepen Response in CLL Patients on Ibrutinib or Acalabrutinib in the Relapsed/Refractory Setting |
[exclusion] use of cyclosporine, corticosteroids or psoralen + UVA (PUVA) treatment within 4 weeks | A Randomized, Double Blind, Placebo-controlled Proof-of-concept Study of FP187 in Patients With Mild to Moderate Psoriatic Arthritis |
[inclusion] biologics: At least 90 days, or 5 half-lives, whichever is shorter, since the completion of therapy with an antineoplastic biologic agent | A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation |
[exclusion] use of botulinum toxin therapy of any serotype for any urological condition | OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder |
[inclusion] no prior use of antiretroviral therapy | MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) |
[exclusion] participants who report treatment with adjunctive or monotherapy antipsychotic treatment during the current depressive episode | A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder |
[inclusion] stable ILD as evident by a stable FEV1 and FVC for 3 months prior to the initiation of the study, and be pulmonary arterial hypertension (PAH)-targeted treatment naïve | CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated Interstitial Lung DiseasE and Pulmonary Hypertension (PH): The CRuSADE PH Study |
[exclusion] recent or debilitating stroke | Exercise Intolerance in Elderly Diastolic Heart Failure |
[exclusion] part 3 Only: Genotyped as poor metabolizer of cytochrome P450 2C19 | A Three-Part Phase 1 Study to Evaluate the Potential Drug Interaction Between ACH-0144471 and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adult Subjects |
[exclusion] non-aneurysmal subarachnoid hemorrhage | Efficacy and Safety of Cilostazol-Nimodipine Combined Therapy on Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial |
[exclusion] patients with clinically significant gastrointestinal (GI) abnormalities that may increase the risk for GI bleeding will not be eligible for participation; these include, but are not limited to: Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other GI conditions with increased risk of perforation | A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas |
[exclusion] histologic subtypes of thyroid cancer other than differentiated (i.e. like anaplastic and medullary carcinoma, lymphoma or sarcoma) | A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer |
[inclusion] PLUS one or more of the following: Bone disease (lytic lesions or osteopenia) | Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone (RCP) for Patients With Newly Diagnosed Multiple Myeloma |
[inclusion] no other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix | Phase II Evaluation Of Paclitaxel, Cisplatin And 5-Fluorouracil Given In Combination With Radiation Therapy Prior To Surgery In Patients With Resectable Esophageal Cancer |
[inclusion] hemoglobin >= 10 gm/dl | Phase I Trial of R115777 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
[exclusion] adrenocorticosteroids (> 3 months at any time or > 10 days within the previous yr) | Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism |
[inclusion] must have progressed on one systemic line of treatment (can include LHRH agonist/antagonist or orchiectomy and one additional line of therapy (abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, etc)) | Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer |
[exclusion] subjects must not have received a live vaccine within 30 days prior to the first dose of study medication | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation |
[exclusion] enzyme-inducing anticonvulsants: Patients who are currently receiving enzyme inducing anticonvulsants are not eligible | A Phase I Study of Sirolimus in Combination With Oral Cyclophosphamide and Oral Topotecan in Children and Young Adults With Relapsed and Refractory Solid Tumors |
[exclusion] risk for drug dependence as evaluated by a psychiatrist | The Effect of Tetrahydrocannabinol on Ocular Hemodynamics in Healthy Subjects |
[inclusion] patients may not have received immunotherapies, biologic and viral therapies, angiogenesis inhibitors, mTOR, or PARP inhibitors | A Phase I Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients With Previously Treated Glioblastoma Multiforme |
[exclusion] risk of reflux | Quantifying Nitrous Oxide Effect on Depth of Anaesthesia Using Theoretically Based Time Series Modelling |
[inclusion] urinary frequency ≥ 8 micturitions on average per 24 hours during the 3-day micturition diary period | Comparison of Solifenacin Combined With Pelvic Floor Muscle and Whole Body Vibration Training With Solifenacin Alone in Patients With Overactive Bladder Syndrome. - A Prospective Randomized Parallel Group Trial |
[inclusion] date of birth to date of enrollment is <1 year | An Open-label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir in the Treatment of Infants Less Than One Year of Age With Influenza Infection |
[exclusion] patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier | Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients |
[exclusion] presence of contraindication to cervical cerclage | Vaginal Progesterone Versus Cervical Cerclage for Pregnant Women With Sonographic Short Cervix and History of Preterm Labor and/or Midtrimester Miscarriage |
[inclusion] peripheral neuropathic character of pain objectified to a score ≥ 4/10 on the DN4 questionnaire | Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain. |
[exclusion] positive stool examinations for C. difficile or other intestinal pathogens < 30 days prior to screening | Mechanism of Action and Clinical Effect of BI 655130 in Patients With Fistulizing Crohn's Disease |
[inclusion] recurrent or progressive disease after chemotherapy or radiotherapy | Phase I Trial of Bortezomib (VELCADE™) and Celecoxib in Patients With Advanced Solid Tumors |